News

FDA approves canagliflozin/metformin combination


 

References

The Food and Drug Administration has approved Invokamet, a fixed-dose combination of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, and metformin, for type 2 diabetes.

Janssen Pharmaceuticals, which will market Invokamet in the United States, says that it’s the first such combination approved by the FDA. Specifically, the indication is "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled by treatment that includes either canagliflozin or metformin, or who are already being treated with both canagliflozin and metformin as separate medications."

The drug will be available in four dosage combinations containing canagliflozin 50 mg or 150 mg and metformin 500 mg or 1000 mg. The recommended dose is twice daily.

Canagliflozin was originally approved by the FDA in March 2013. During three phase III trials of canagliflozin plus metformin, the combination "lowered blood sugar and, in pre-specified secondary endpoints, was associated with significant reductions in body weight and systolic blood pressure," according to the statement. The most common adverse events were female genital mycotic infections, urinary tract infections, and increased urination. The most common adverse reactions with metformin were diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache. Canagliflozin can increase the risk of hypoglycemia when combined with insulin or a sulfonylurea. The company says that lower doses of those therapies may be required to minimize the risk of hypoglycemia when used in combination with Invokamet.

There is also a boxed warning on the potential for lactic acidosis.

aault@frontlinemedcom.com

On Twitter @aliciaault

Recommended Reading

Additional chronic conditions seen in 87% of diabetes patients
MDedge Internal Medicine
Mindfulness meditation helped veterans with diabetes management
MDedge Internal Medicine
VIDEO: Mindfulness potential tool for diabetes patients to cope with stress
MDedge Internal Medicine
Data increasingly support plant-based diet for diabetes prevention, care
MDedge Internal Medicine
Long-term benefits shown after gastric banding
MDedge Internal Medicine
A low-fat vegan diet may lessen diabetic neuropathy pain
MDedge Internal Medicine
VIDEO: Tips from AADE’s Diabetes Educator of the Year
MDedge Internal Medicine
DAWN2: Addressing emotional distress may improve diabetes self management
MDedge Internal Medicine
VIDEO: DAWN2 shows need for patient-centered care in diabetes
MDedge Internal Medicine
Diabetes education should seek to improve health care literacy
MDedge Internal Medicine

Related Articles